F9 and hemophilia B: A clinical study in six patients with severe hemophilia B demonstrated that a peripherally administered AAV vector expressing human factor IX resulted in stable expression at 2–11% of normal levels, which was sufficient to ameliorate the bleeding diathesis [69].